Targeted therapy for prostate cancer

Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and limits damage to healthy cells.


Targeted therapy for prostate cancer includes:

Olaparib (Lynparza): Olaparib is a PARP inhibitor, which is a type of targeted therapy. It is supported for patients with metastatic maiming safe prostate disease whose sickness has proceeded to develop and spread during therapy with abiraterone or potentially enzalutamide and who have DNA-fix quality deformities, which might be acquired or in the growth. Cancer cells have a harder time repairing damaged DNA because of defects in DNA repair genes. DNA-repair gene defects are associated with certain genes, including BRCA1, BRCA2, and a number of others; the presence of any of these genes makes olaparib treatment possible. The FDA has likewise endorsed 2 explicit tests to choose patients for treatment with olaparib.

Rucaparib (Rubraca): Rucaparib is another approved PARP inhibitor for the treatment of metastatic castration-resistant prostate cancer in patients with an inherited or tumor-associated BRCA1 or BRCA2 mutation whose disease has not been controlled by abiraterone, enzalutamide, or chemotherapy.

One or more tests must be given to determine whether a patient may receive olaparib or rucaparib:

  • Testing for an inherited, or germline, mutation after discussion with a genetic counselor

  • Genomic sequencing of tumor tissue

  • Genomic sequencing of the tumor DNA floating in the bloodstream

Tissue from a new biopsy or tissue from a previous collection can both be subjected to genomic sequencing. Germline transformation testing alone distinguishes about a portion of the patients qualified for this treatment. All three of the aforementioned tests should be discussed with patients with metastatic prostate cancer who are considering targeted therapy.


Dr. Amit Ghosh is one of the best urologist and robotics uro-surgeon in Kolkata. After his return from the UK, he has been associated with various institutions including Wockhardt Hospital and Kidney Institute, Woodlands Hospital, Kothari Medical Center and Anandalok Hospital. Currently he is dedicated to his service to Apollo Gleneagles Hospitals, Kolkata. Currently he has developed a very well established and robust Urological presence in the campus of Apollo Gleneagles Hospitals, Kolkata. The practice takes care of all fundamental general Urological procedures, a vast multi-disciplinary Uro Oncology specialty, and also a comprehensive diagnostic and uro health check-up facility.

Comments

Popular posts from this blog

Arrhythmia surgery

CANCER AND MENTAL HEALTH- IT DOESN’T JUST AFFECT YOUR BODY

Blood Cancer- Part 2